Probiotics vs placebo
- Probiotics for the prevention of Hirschsprung‐associated enterocolitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsGRADE not reported
The review found no eligible studies for this question.
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with control (very low certainty).
Probiotics showed no clear difference in adverse events (serious adverse reaction and adverse reaction) compared with placebo (low certainty).
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Probiotics used as adjuvants to conventional antifungal drugs showed no clear difference in rate of serious adverse events compared with conventional antifungal drugs (low certainty).